» Articles » PMID: 26462859

Differential Expression of Key Regulators of Toll-like Receptors in Ulcerative Colitis and Crohn's Disease: a Role for Tollip and Peroxisome Proliferator-activated Receptor Gamma?

Overview
Date 2015 Oct 15
PMID 26462859
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

The innate immune system is currently seen as the probable initiator of events which culminate in the development of inflammatory bowel disease (IBD) with Toll-like receptors (TLRs) known to be involved in this disease process. Many regulators of TLRs have been described, and dysregulation of these may also be important in the pathogenesis of IBD. The aim of this study was to perform a co-ordinated analysis of the expression levels of both key intestinal TLRs and their inhibitory proteins in the same IBD cohorts, both ulcerative colitis (UC) and Crohn's disease (CD), in order to evaluate the potential roles of these proteins in the pathogenesis of IBD. Of the six TLRs (TLRs 1, 2, 4, 5, 6 and 9) examined, only TLR-4 was increased significantly in IBD, specifically in active UC. In contrast, differential alterations in expression of TLR inhibitory proteins were observed. A20 and suppressor of cytokine signalling 1 (SOCS1) were increased only in active UC while interleukin-1 receptor-associated kinase 1 (IRAK-m) and B cell lymphoma 3 protein (Bcl-3) were increased in both active UC and CD. In contrast, expression of both peroxisome proliferator-activated receptor gamma (PPARγ) and Toll interacting protein (Tollip) was decreased in both active and inactive UC and CD and at both mRNA and protein levels. In addition, expression of both PPARγ and A20 expression was increased by stimulation of a colonic epithelial cell line Caco-2 with both TLR ligands and commensal bacterial strains. These data suggest that IBD may be associated with distinctive changes in TLR-4 and TLR inhibitory proteins, implying that alterations in these may contribute to the pathogenesis of IBD.

Citing Articles

Associations between genetic variants of Toll-interacting proteins and interstitial lung diseases: a systematic review and meta-analysis.

Li X, Cui B, Jiang L Orphanet J Rare Dis. 2024; 19(1):432.

PMID: 39578840 PMC: 11583435. DOI: 10.1186/s13023-024-03410-8.


The Versatile Role of Peroxisome Proliferator-Activated Receptors in Immune-Mediated Intestinal Diseases.

Posta E, Fekete I, Varkonyi I, Zold E, Barta Z Cells. 2024; 13(20.

PMID: 39451206 PMC: 11505700. DOI: 10.3390/cells13201688.


The Contribution of Genetic and Epigenetic Factors: An Emerging Concept in the Assessment and Prognosis of Inflammatory Bowel Diseases.

Minea H, Singeap A, Minea M, Juncu S, Muzica C, Sfarti C Int J Mol Sci. 2024; 25(15).

PMID: 39125988 PMC: 11313574. DOI: 10.3390/ijms25158420.


Toll-like Receptors and Cytokine Modulation by Goat Milk Extracellular Vesicles in a Model of Intestinal Inflammation.

De Ciucis C, Fruscione F, De Paolis L, Mecocci S, Zinellu S, Guardone L Int J Mol Sci. 2023; 24(13).

PMID: 37446274 PMC: 10341995. DOI: 10.3390/ijms241311096.


Xuanhuang Runtong Tablets Relieve Slow Transit Constipation in Mice by Regulating TLR5/IL-17A Signaling Mediated by Gut Microbes.

Liang X, Wan D, Cai Y, Yue W, Wang X, Zhou H Evid Based Complement Alternat Med. 2023; 2023:6506244.

PMID: 36700038 PMC: 9870700. DOI: 10.1155/2023/6506244.


References
1.
Frolova L, Drastich P, Rossmann P, Klimesova K, Tlaskalova-Hogenova H . Expression of Toll-like receptor 2 (TLR2), TLR4, and CD14 in biopsy samples of patients with inflammatory bowel diseases: upregulated expression of TLR2 in terminal ileum of patients with ulcerative colitis. J Histochem Cytochem. 2007; 56(3):267-74. PMC: 2324181. DOI: 10.1369/jhc.7A7303.2007. View

2.
Garlanda C, Anders H, Mantovani A . TIR8/SIGIRR: an IL-1R/TLR family member with regulatory functions in inflammation and T cell polarization. Trends Immunol. 2009; 30(9):439-46. DOI: 10.1016/j.it.2009.06.001. View

3.
Loh G, Blaut M . Role of commensal gut bacteria in inflammatory bowel diseases. Gut Microbes. 2012; 3(6):544-55. PMC: 3495792. DOI: 10.4161/gmic.22156. View

4.
Annese V, Rogai F, Settesoldi A, Bagnoli S . PPARγ in Inflammatory Bowel Disease. PPAR Res. 2012; 2012:620839. PMC: 3444923. DOI: 10.1155/2012/620839. View

5.
Garlanda C, Riva F, Veliz T, Polentarutti N, Pasqualini F, Radaelli E . Increased susceptibility to colitis-associated cancer of mice lacking TIR8, an inhibitory member of the interleukin-1 receptor family. Cancer Res. 2007; 67(13):6017-21. DOI: 10.1158/0008-5472.CAN-07-0560. View